Navigate the next curve in drug development
AI, real-world data and new research models are expanding what is possible in drug development. But progress depends on more than adopting new capabilities. Teams need to understand which approaches are ready to use, where stronger validation is needed, and what must change to turn innovation into trusted evidence.
In The Change Curve: How Far, How Fast?, we examine ten shifts shaping drug development and evidence generation — from agentic AI and hybrid trials to the European Health Data Space and federated research. The report explores what is changing, what is slowing progress, and what will determine how far and how fast each shift advances.
Read it to help your team assess what these changes mean for your evidence strategy, identify gaps earlier, and make better-informed decisions about where to focus next.